drugset / Trial / NCT01671488
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
Phase 1/2
Terminated
11 enrolled
Brown University
Rhode Island Hospital · collabThe Miriam Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to study the safety and effectiveness of ADXS11-001 when combined with standard chemotherapy and radiation treatment for anal cancer. ADXS11-001 is an investigational agent that is not approved by the FDA to treat anal cancer or any other cancer.
Timeline
- Start
- 2013-02
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADXS11-001 | Vaccine | 1e+09 unknown | Intravenous |
| Background | Mitomycin C | Other / unclassified | 10 mg/m2 | — |
| Background | fluorouracil | Small molecule | 1 g | — |